Endogenous nitric oxide inhibits spinal NMDA receptor activity and pain hypersensitivity induced by nerve injury

Neuropharmacology. 2017 Oct:125:156-165. doi: 10.1016/j.neuropharm.2017.07.023. Epub 2017 Jul 25.

Abstract

The role of nitric oxide (NO) in nociceptive transmission at the spinal cord level remains uncertain. Increased activity of spinal N-methyl-d-aspartate (NMDA) receptors contributes to development of chronic pain induced by peripheral nerve injury. In this study, we determined how endogenous NO affects NMDA receptor activity of spinal cord dorsal horn neurons in control and spinal nerve-ligated rats. Bath application of the NO precursor l-arginine or the NO donor S-nitroso-N-acetylpenicillamine (SNAP) significantly inhibited NMDA receptor currents of spinal dorsal horn neurons in both sham control and nerve-injured rats. Inhibition of neuronal nitric oxide synthase (nNOS) or blocking the S-nitrosylation reaction with N-ethylmaleimide abolished the inhibitory effects of l-arginine on NMDA receptor currents recorded from spinal dorsal horn neurons in sham control and nerve-injured rats. However, bath application of the cGMP analog 8-bromo-cGMP had no significant effects on spinal NMDA receptor currents. Inhibition of soluble guanylyl cyclase also did not alter the inhibitory effect of l-arginine on spinal NMDA receptor activity. Furthermore, knockdown of nNOS with siRNA abolished the inhibitory effects of l-arginine, but not SNAP, on spinal NMDA receptor activity in both groups of rats. Additionally, intrathecal injection of l-arginine significantly attenuated mechanical or thermal hyperalgesia induced by nerve injury, and the l-arginine effect was diminished in rats treated with a nNOS inhibitor or nNOS-specific siRNA. These findings suggest that endogenous NO inhibits spinal NMDA receptor activity through S-nitrosylation. NO derived from nNOS attenuates spinal nociceptive transmission and neuropathic pain induced by nerve injury.

Keywords: Dorsal horn neurons; Ion channel; Neuropathic pain; Signal transduction; Synaptic plasticity; Synaptic transmission.

MeSH terms

  • Analgesics, Non-Narcotic / pharmacology*
  • Animals
  • Arginine / pharmacology
  • Central Nervous System Agents / pharmacology
  • Cyclic GMP / analogs & derivatives
  • Cyclic GMP / pharmacology
  • Disease Models, Animal
  • Ethylmaleimide / pharmacology
  • Excitatory Amino Acid Antagonists / pharmacology
  • Hot Temperature
  • Hyperalgesia / drug therapy*
  • Hyperalgesia / metabolism
  • Male
  • Neuralgia / drug therapy
  • Neuralgia / metabolism
  • Nitric Oxide / pharmacology*
  • Nitric Oxide Synthase Type I / antagonists & inhibitors
  • Nitric Oxide Synthase Type I / metabolism
  • Posterior Horn Cells / drug effects*
  • Posterior Horn Cells / metabolism
  • Rats, Sprague-Dawley
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*
  • Receptors, N-Methyl-D-Aspartate / metabolism
  • S-Nitroso-N-Acetylpenicillamine / pharmacology
  • Soluble Guanylyl Cyclase / antagonists & inhibitors
  • Soluble Guanylyl Cyclase / metabolism
  • Spinal Nerves / drug effects
  • Spinal Nerves / injuries*
  • Spinal Nerves / metabolism
  • Tissue Culture Techniques
  • Touch

Substances

  • Analgesics, Non-Narcotic
  • Central Nervous System Agents
  • Excitatory Amino Acid Antagonists
  • Receptors, N-Methyl-D-Aspartate
  • 8-bromocyclic GMP
  • Nitric Oxide
  • S-Nitroso-N-Acetylpenicillamine
  • Arginine
  • Nitric Oxide Synthase Type I
  • Nos1 protein, rat
  • Soluble Guanylyl Cyclase
  • Cyclic GMP
  • Ethylmaleimide